Excelsior Biopharma Cash Flow Conversion Efficiency
Excelsior Biopharma cash flow conversion efficiency. Based on the latest financial reports, Excelsior Biopharma (6496) has a cash flow conversion efficiency ratio of -0.029x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-20.04 Million ≈ $-631.31K USD) by net assets (NT$688.99 Million ≈ $21.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Excelsior Biopharma (2017–2025)
Cash flow conversion efficiency of Excelsior Biopharma from 2017 to 2025. This chart illustrates how Excelsior Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 6496 share price today for real-time trading data and today's change.
Excelsior Biopharma Cash Flow Conversion Ratio Explained
Excelsior Biopharma cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Excelsior Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Excelsior Biopharma ranked by their cash flow conversion efficiency. Also see Excelsior Biopharma stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lotte Chilsung Beverage Co Ltd
KO:005305
|
0.059x |
|
MBL Infrastructure Limited
NSE:MBLINFRA
|
0.003x |
|
01 Communique Laboratory Inc
V:ONE
|
-0.106x |
|
DONGJIANG ENVIRONMENTAL H
F:DGN
|
N/A |
|
Yanaprima Hastapersada Tbk
JK:YPAS
|
0.171x |
|
Anteotech Ltd
AU:ADO
|
-0.264x |
|
Rent.com.Au Ltd
AU:RNT
|
-0.200x |
|
Plata Latina Minerals Corp
V:PLA
|
-0.097x |
Annual Cash Flow Conversion Efficiency for Excelsior Biopharma (2017–2025)
The table below shows the annual cash flow conversion efficiency of Excelsior Biopharma from 2017 to 2025. Review 6496 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$804.23 Million ≈ $25.34 Million |
NT$-138.72 Million ≈ $-4.37 Million |
-0.172x | -71.36% |
| 2024-12-31 | NT$991.45 Million ≈ $31.24 Million |
NT$-99.80 Million ≈ $-3.14 Million |
-0.101x | +17.50% |
| 2023-12-31 | NT$1.10 Billion ≈ $34.80 Million |
NT$-134.75 Million ≈ $-4.25 Million |
-0.122x | -2785.29% |
| 2022-12-31 | NT$1.21 Billion ≈ $38.04 Million |
NT$5.49 Million ≈ $172.84K |
0.005x | -89.99% |
| 2021-12-31 | NT$1.23 Billion ≈ $38.76 Million |
NT$55.82 Million ≈ $1.76 Million |
0.045x | -88.82% |
| 2020-12-31 | NT$1.28 Billion ≈ $40.42 Million |
NT$520.81 Million ≈ $16.41 Million |
0.406x | +400.08% |
| 2019-12-31 | NT$1.25 Billion ≈ $39.53 Million |
NT$-169.74 Million ≈ $-5.35 Million |
-0.135x | -246.36% |
| 2018-12-31 | NT$1.37 Billion ≈ $43.26 Million |
NT$126.92 Million ≈ $4.00 Million |
0.092x | -64.57% |
| 2017-12-31 | NT$1.34 Billion ≈ $42.21 Million |
NT$349.47 Million ≈ $11.01 Million |
0.261x | -- |
About Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specia… Read more